Accuray (ARAY)
has really never enjoyed smooth sailing. Not only has the company
sought to break into the radiation oncology space (at the expense of
strong incumbents Varian (VAR) and Elekta (EKTAY.PK), but it has done so
at a time when hospital capital budgets are already under a great deal
of strain. More recently, the company executed a controversial
acquisition of TomoTherapy, and while the company has made good progress
on margin improvements, order growth has been elusive.
Continue here:
Will New Leadership Bring Evolution Or Revolution To Accuray?
No comments:
Post a Comment